In fairness, the quarterly did mention DEP Gemcitabine as (still) at the pre-clinical stage. I wonder if they are trying to find someone else to pay for the trial? Regardless of how long it takes.
Business development activities for DEP® cabazitaxel, DEP® irinotecan, and DEP® docetaxel are ongoing. Other internal preclinical DEP® programs including DEP® radiotheranostics, DEP® ADCs, and DEP® gemcitabine continue to progress, with ongoing commercial discussions in parallel.
- Forums
- ASX - By Stock
- SPL
- Status quo to win out?
Status quo to win out?, page-5
-
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $40.00M |
Open | High | Low | Value | Volume |
9.8¢ | 10.5¢ | 9.6¢ | $210.8K | 2.098M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 30408 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 3523 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30408 | 0.095 |
2 | 15638 | 0.094 |
3 | 83394 | 0.093 |
1 | 8435 | 0.091 |
2 | 41000 | 0.090 |
Price($) | Vol. | No. |
---|---|---|
0.095 | 2000 | 1 |
0.097 | 7812 | 1 |
0.105 | 69848 | 2 |
0.110 | 114099 | 6 |
0.115 | 77331 | 6 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online